Research programme: boron-based small molecule therapeutics - AN2 Therapeutics
Latest Information Update: 09 Nov 2023
At a glance
- Originator AN2 Therapeutics
- Class Antibacterials; Antimalarials; Organic boron compounds; Small molecules
- Mechanism of Action Aminoacyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Malaria; Tuberculosis